Global pharma companies and Japan can create a win-win situation through a new pricing mechanism, writes Nobuko Kobayashi.
Nobuko Kobayashi
Advertisement
Nobuko Kobayashi is a partner in global management consulting firm A.T. Kearney’s Consumer Goods and Retail Practice, serving Japanese and multinational clients in consumer industries.
Articles by Nobuko Kobayashi
Innovations in Big Data will have a lasting impact on care and present an opportunity for U.S. pharmaceutical companies, writes Nobuko Kobayashi.
Advertisement
Latest Updated Articles
Japan: Balancing Cost and Innovation through PricingJuly 9th 2018
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5